Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LPL | P06858 | 6/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20995580 | 0.85 | SMN1; SMN2 (0.53) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL21234562 | 0.85 | HIF1A (0.44) | ALDH1A1LPLLIPGTDP1CA1 | |
| SCHEMBL5899727 | 0.84 | LPL (0.65) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL623833 | 0.84 | CA1 (0.54) | ALDH1A1LPLLIPGTDP1CA1 | |
| SCHEMBL17423486 | 0.84 | LIPG (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29719698 | 0.84 | LIPG (0.51) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL13860162 | 0.84 | LIPG (0.51) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL5243207 | 0.83 | CA1 (0.61) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20995794 | 0.81 | LIPG (0.43) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1128720 | 0.81 | AR (0.52) | ALDH1A1LPLLIPGTDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481831-B1 | 4-AMINOPYRAZOLO[3,4-D]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2023-09-06 | — | — | EP | disclosed |
| EP-3481831-B1 | 4-AMINOPYRAZOLO[3,4-D]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2023-09-06 | — | — | EP | disclosed |
| CN-109153680-B | 4-aminopyrazolo [3,4-d ] pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2021-04-23 | — | — | CN | disclosed |
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-03 | — | — | US | disclosed |
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-03 | — | — | US | disclosed |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | ITK, BTK, TYK2 | ALDH1A1 4364/4885LPL 3509/4885LIPG 2907/4885 |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | BTK, ITK, TYK2 | ALDH1A1 4464/4885LPL 3509/4885LIPG 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.